Latest news with #SunPharmaceutical
&w=3840&q=100)
Business Standard
2 days ago
- Business
- Business Standard
Sun Pharma halts development of SCD-044 drug after trial disappointment
Sun Pharmaceutical Industries on Tuesday announced that it will discontinue development of its experimental oral drug, SCD-044, following disappointing results in Phase 2 clinical trials for the treatment of moderate to severe psoriasis and atopic dermatitis (eczema). The trial did not achieve the primary objective: a 75 per cent improvement in the EASI (Eczema Area and Severity Index) score by Week 16, the company said. The Phase 2 clinical trial enrolled 250 patients and compared three different dosages of SCD-044 with a placebo. The study followed a randomised, double-blind, placebo-controlled design—standard methodology intended to minimise bias in clinical research. 'While we are disappointed with the top-line results of the clinical trials, we would like to thank all the psoriasis and atopic dermatitis patients, the healthcare professionals and administrators who participated in these pivotal clinical trials,' said Dr Marek Honczarenko, Senior Vice-President and Head of Global Specialty Development at Sun Pharma. Shares of Sun Pharmaceutical closed at ₹1,667.65 on Tuesday, down ₹7.25 or 0.43 per cent. In the fourth quarter of FY25, the company reported a 19 per cent year-on-year decline in net profit to ₹2,153.9 crore, compared with ₹2,658.74 crore in the same quarter of the previous fiscal.
Business Upturn
29-05-2025
- Business
- Business Upturn
Nifty 50 top gainers today, May 29: IndusInd Bank, Sun Pharmaceutical, Eternal, Adani Ports, Trent and more
Indian equity markets showcased a decent rally on May 29, with benchmark indices ending the day in the green. The BSE Sensex surged 320.70 points or 0.39%, closing at 81,633.02, while the Nifty 50 advanced 81.15 points or 0.33%, to settle at 24,833.60. Among the Nifty 50 stocks, several companies recorded significant gains, led by IndusInd Bank, Sun Pharmaceutical and Eternal. Below is a detailed look at the top gainers of the Nifty 50 (as per Trendline) for the day. Nifty 50 Top Gainers on May 29 IndusInd Bank closed at ₹824.2, up by ₹19.00 or 2.4% . Sun Pharmaceutical Industries ended at ₹1699.5, gaining ₹33.10 or 2.0% . Eternal closed at ₹228.4, rising ₹4.19 or 1.9% . Adani Ports & Special Economic Zone ended the session at ₹1435.5, up by ₹24.50 or 1.7% . Trent closed at ₹5651.0, with a gain of ₹92.00 or 1.7% . Tech Mahindra finished at ₹1602.0, increasing ₹21.70 or 1.4% . Wipro closed at ₹250.5, up ₹3.09 or 1.3% . Tata Steel ended the day at ₹163.1, rising ₹1.88 or 1.2% . Adani Enterprises closed at ₹2543.0, with a gain of ₹28.00 or 1.1% . Eicher Motors finished at ₹5385.0, up ₹58.50 or 1.1%. Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information. Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
&w=3840&q=100)
Business Standard
22-05-2025
- Business
- Business Standard
Sun Pharma results: Profit down 19% at Rs 2,149.8 cr, revenue up 8%
India's largest drug maker Sun Pharmaceutical on Thursday posted a decline of 19 per cent year-on-year (Y-o-Y) for its consolidated net profit for the fourth quarter of the financial year 2025 (Q4FY25) at ₹2,149.8 crore. Meanwhile, its revenue from operations rose by 8 per cent at ₹12,958.8 crore. Barring an exceptional item, the company's net profit for the quarter will come to ₹2,889.1 crore, rising 4.8 per cent. Sun Pharma attributed the lower growth in the quarter partly to softer sales in January and February in the US, which is a typical trend. However, the company clarified that there is no specific product driving this and that overall prescription and inventory trends for key brands remains strong. The fall in the net profit can also be attributed to the rise in input costs compared to last year. For FY25, Sun's net profit surged by 14 per cent Y-o-Y, reaching ₹10,929 crore. While revenue from operations also grew by 8 per cent, reaching ₹52,578 crore. Both net profit and revenue missed Bloomberg estimates, falling short by 23 per cent and 2.23 per cent, respectively. On Thursday, Sun Pharma's share fell by 0.74 per cent ending the day's trade at ₹1718.70. The results came after market hours. On the legal front, Sun Pharma reported an exceptional item of ₹677.8 crore for the full year, related to a legal settlement in the US. In a key development, the company — previously awaiting the outcome of the Leqselvi (a hair loss treatment inhibitor) litigation — announced that the United States Court of Appeals has reversed its earlier ruling and vacated the preliminary injunction, now allowing for the commercial launch of Leqselvi. Sun Pharma will now launch Leqselvi in Q2FY26. Dilip Shanghvi, chairman and managing director of Sun Pharmaceuticals, said, 'The nearterm pipeline in global specialty is promising, with products such as Leqselvi and Unloxcyt — the latter through our recently announced Checkpoint acquisition — offering significant improvements in patient care.' Sun Pharma announced updates to its global specialty pipeline, stating that it is now seeking a partner for the development and commercialisation of MM-II (used for treatment of knee osteoarthritis pain) in select geographies, following a strategic reassessment. The company reaffirmed its confidence in the product's potential. Additionally, it plans to initiate clinical trials of GL0034 (Utreglutide), a peptide-1 receptor with type 2 diabetes as the first target indication. The company expects a mid to high single-digit consolidated top-line growth for FY26. Sun Pharma also plans to invest around $100 million this year to support the commercialisation of a new specialty product. This investment is aimed at significantly strengthening its specialty business in the long term. The company views this as a strategic investment to deepen its presence and growth in the specialty segment. The domestic formulations sales for FY25 India sales rose by 13.7 per cent which stood at ₹16,923 crore, up 13.7 per cent Y-o-Y. For the quarter, sales were up by 13.6 per cent reaching ₹4,213 crore, contributing 33 per cent to total quarterly revenue. The company launched 10 new products in the quarter. US formulations sales which accounts for 31.4 per cent of total revenue for the quarter fell by 2.5 per cent to $464 million. For FY25, the sales rose by 3.6 per cent Y-o-Y at $1,921 million. The global specialty revenue rose by 17 per cent Y-o-Y to $1,216 million for the full year, while for the quarter the sales grew by 8.6 per cent to $295 million contributing 19.9 per cent to total revenue. The emerging markets sales rose by 7 per cent Y-o-Y to $1,114 million in FY25. For the quarter the sales rose by 6.3 per cent forming 17 per cent of the revenue. The rest of world (RoW) region accounting for 13 per cent of revenue saw a growth of 2 per cent for the quarter at $200 million. For the year the sales increased by 4.5 per cent at $847 million. The active pharmaceutical ingredient (API) business grew by 11 per cent Y-o-Y at ₹2,129 crore in FY25, in Q4 sales were up by 28 per cent at ₹533 crore. Sun's consolidated research and development (R&D) investment for the year was ₹3,248 crore or 6.2 per cent of sales. In Q4 it stood at ₹817 crore or 6.4 per cent of sales. The specialty pipeline includes 8 novel clinical-stage entities.
&w=3840&q=100)
Business Standard
22-05-2025
- Business
- Business Standard
Sun Pharma Q4 results: Profit down 19% at Rs 2,149.8 cr, revenue up 8%
India's largest drug maker Sun Pharmaceutical on Thursday posted a decline of 19 per cent year-on-year (Y-o-Y) for its consolidated net profit for the fourth quarter of the financial year 2025 (Q4FY25) at ₹2,149.8 crore. Meanwhile, its revenue from operations rose by 8 per cent at ₹12,958.8 crore. Barring an exceptional item, the company's net profit for the quarter will come to ₹2,889.1 crore, rising 4.8 per cent. Sun Pharma attributed the lower growth in the quarter partly to softer sales in January and February in the US, which is a typical trend. However, the company clarified that there is no specific product driving this and that overall prescription and inventory trends for key brands remains strong. The fall in the net profit can also be attributed to the rise in input costs compared to last year. For FY25, Sun's net profit surged by 14 per cent Y-o-Y, reaching ₹10,929 crore. While revenue from operations also grew by 8 per cent, reaching ₹52,578 crore. Both net profit and revenue missed Bloomberg estimates, falling short by 23 per cent and 2.23 per cent, respectively. On Thursday, Sun Pharma's share fell by 0.74 per cent ending the day's trade at ₹1718.70. The results came after market hours. On the legal front, Sun Pharma reported an exceptional item of ₹677.8 crore for the full year, related to a legal settlement in the US. In a key development, the company — previously awaiting the outcome of the Leqselvi (a hair loss treatment inhibitor) litigation — announced that the United States Court of Appeals has reversed its earlier ruling and vacated the preliminary injunction, now allowing for the commercial launch of Leqselvi. Sun Pharma will now launch Leqselvi in Q2FY26. Dilip Shanghvi, chairman and managing director of Sun Pharmaceuticals, said, 'The nearterm pipeline in global specialty is promising, with products such as Leqselvi and Unloxcyt — the latter through our recently announced Checkpoint acquisition — offering significant improvements in patient care.' Sun Pharma announced updates to its global specialty pipeline, stating that it is now seeking a partner for the development and commercialisation of MM-II (used for treatment of knee osteoarthritis pain) in select geographies, following a strategic reassessment. The company reaffirmed its confidence in the product's potential. Additionally, it plans to initiate clinical trials of GL0034 (Utreglutide), a peptide-1 receptor with type 2 diabetes as the first target indication. The company expects a mid to high single-digit consolidated top-line growth for FY26. Sun Pharma also plans to invest around $100 million this year to support the commercialisation of a new specialty product. This investment is aimed at significantly strengthening its specialty business in the long term. The company views this as a strategic investment to deepen its presence and growth in the specialty segment. The domestic formulations sales for FY25 India sales rose by 13.7 per cent which stood at ₹16,923 crore, up 13.7 per cent Y-o-Y. For the quarter, sales were up by 13.6 per cent reaching ₹4,213 crore, contributing 33 per cent to total quarterly revenue. The company launched 10 new products in the quarter. US formulations sales which accounts for 31.4 per cent of total revenue for the quarter fell by 2.5 per cent to $464 million. For FY25, the sales rose by 3.6 per cent Y-o-Y at $1,921 million. The global specialty revenue rose by 17 per cent Y-o-Y to $1,216 million for the full year, while for the quarter the sales grew by 8.6 per cent to $295 million contributing 19.9 per cent to total revenue. The emerging markets sales rose by 7 per cent Y-o-Y to $1,114 million in FY25. For the quarter the sales rose by 6.3 per cent forming 17 per cent of the revenue. The rest of world (RoW) region accounting for 13 per cent of revenue saw a growth of 2 per cent for the quarter at $200 million. For the year the sales increased by 4.5 per cent at $847 million. The active pharmaceutical ingredient (API) business grew by 11 per cent Y-o-Y at ₹2,129 crore in FY25, in Q4 sales were up by 28 per cent at ₹533 crore. Sun's consolidated research and development (R&D) investment for the year was ₹3,248 crore or 6.2 per cent of sales. In Q4 it stood at ₹817 crore or 6.4 per cent of sales. The specialty pipeline includes 8 novel clinical-stage entities. The company has 542 approved abbreviated new drug applications (ANDA) and 117 pending with the US Food and Drug Administration, including 33 tentative.
Reuters
22-05-2025
- Business
- Reuters
India's Sun Pharma posts quarterly profit rise on strong demand for rare disease drugs
May 22 (Reuters) - Sun Pharmaceutical ( opens new tab, India's largest drugmaker by revenue, reported a rise in adjusted quarterly profit on Thursday, driven by strong domestic demand for its drugs to treat rare diseases. The Mumbai-based firm's consolidated profit before exceptional items and tax rose 24% to 36.16 billion rupees ($420.7 million) in the three months ended March 31. ($1 = 85.9500 Indian rupees)
